web_16x9_lg-GettyImages-1093747624
Photo: Hocevar_Grega_GHphotoqraphy/Getty Images
FDA clears application for CRISPR RNA-editing therapy developed using AI
By Jessica Hagen
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat neovascular age-related macular degeneration (nAMD), dubbed HG202, developed using machine learning and AI.
The company used its HG-PRECISE platform (HuidaGene – Platform for Rational Engineering of CRISPR-Cas Identification by Synergic Expertise) to devise the therapy.
HG-PRECISE allows for the quick discovery of Cas proteins using AI and machine learning in DNA sequencing. It also provides assembly predictions from a metagenomic database.
